Discovery and Optimization of Phosphopantetheine Adenylyltransferase Inhibitors with Gram-Negative Antibacterial Activity.
Skepper, C.K., Moreau, R.J., Appleton, B.A., Benton, B.M., Drumm, J.E., Feng, B.Y., Geng, M., Hu, C., Li, C., Lingel, A., Lu, Y., Mamo, M., Mergo, W., Mostafavi, M., Rath, C.M., Steffek, M., Takeoka, K.T., Uehara, K., Wang, L., Wei, J.R., Xie, L., Xu, W., Zhang, Q., de Vicente, J.(2018) J Med Chem 61: 3325-3349
- PubMed: 29551072 
- DOI: 10.1021/acs.jmedchem.7b01861
- Primary Citation of Related Structures:  
6CHL, 6CHM, 6CHN, 6CHO, 6CHP, 6CHQ, 6CKW - PubMed Abstract: 
In the preceding manuscript [ Moreau et al. 2018 , 10.1021/acs.jmedchem.7b01691 ] we described a successful fragment-based lead discovery (FBLD) strategy for discovery of bacterial phosphopantetheine adenylyltransferase inhibitors (PPAT, CoaD). Following several rounds of optimization two promising lead compounds were identified: triazolopyrimidinone 3 and 4-azabenzimidazole 4 ...